RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Denali Therapeutics Stock

Denali Therapeutics Stocks 2024

Denali Therapeutics Stocks

137.37 M

Ticker

DNLI

ISIN

US24823R1059

WKN

A2H9G8

In 2024, Denali Therapeutics had 137.37 M outstanding stocks, a 0% change from the 137.37 M stocks in the previous year.

The Denali Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e137.37
2028e137.37
2027e137.37
2026e137.37
2025e137.37
2024e137.37
2023137.37
2022125.5
2021121.5
2020112.7
201995.6
201892.6
201787.5
201682.4
201582.4

Denali Therapeutics shares outstanding

The number of shares was Denali Therapeutics in 2023 — This indicates how many shares 137.371 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Denali Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Denali Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Denali Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Denali Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Denali Therapeutics Aktienanalyse

What does Denali Therapeutics do?

Denali Therapeutics Inc is a biotechnology company specializing in the research and development of therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company was founded in 2015 by four former employees of Genentech, with the goal of finding innovative treatments for serious neurological conditions. Denali Therapeutics' business model is based on a patented platform technology that allows the company to target and deliver its drugs precisely to the brain of patients. The company utilizes "liposomes," microscopic bubbles of fat that are loaded with the drug and then transported to the brain through the bloodstream. Denali Therapeutics is divided into three divisions: development platform, therapy development, and diagnosis development. The development platform is the core business of Denali Therapeutics. Here, the company continues to develop its liposome technology to be used for various neurological diseases. The therapy development focuses on developing targeted drugs for specific neurodegenerative diseases. Denali Therapeutics collaborates closely with neurologists and other experts to develop the best possible therapies for patients. The diagnosis development aims to detect early symptoms of neurodegenerative diseases, enabling early diagnosis and treatment. Denali Therapeutics is primarily working on the development of testing methods that will allow for early detection of Alzheimer's and Parkinson's. Currently, Denali Therapeutics has several promising drugs in its pipeline. One of the most important projects is a drug for Alzheimer's disease, which is currently being tested in clinical trials. The drug targets the accumulation of beta-amyloid, which is responsible for the progression of the disease. Another promising project is a drug for Parkinson's, which is also being tested in clinical trials. The drug targets the accumulation of alpha-synuclein, a protein implicated in the development of Parkinson's. Denali Therapeutics aims to develop new therapies for neurodegenerative diseases to improve the lives of patients. The company is committed to answering the many unanswered medical questions in the field of neurology and making a contribution to overcoming these serious diseases. Denali Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Denali Therapeutics's Shares Outstanding

Denali Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Denali Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Denali Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Denali Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Denali Therapeutics stock

How many stocks are there of Denali Therapeutics?

The current number of stocks of Denali Therapeutics is 137.37 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Denali Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Denali Therapeutics evolved in recent years?

The number of shares of Denali Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Denali Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Denali Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Denali Therapeutics pay?

Over the past 12 months, Denali Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Denali Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Denali Therapeutics?

The current dividend yield of Denali Therapeutics is .

When does Denali Therapeutics pay dividends?

Denali Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Denali Therapeutics?

Denali Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Denali Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Denali Therapeutics located?

Denali Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Denali Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Denali Therapeutics from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Denali Therapeutics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Denali Therapeutics in the year 2023?

In the year 2023, Denali Therapeutics distributed 0 USD as dividends.

In which currency does Denali Therapeutics pay out the dividend?

The dividends of Denali Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Denali Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Denali Therapeutics

Our stock analysis for Denali Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Denali Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.